Compare iShares 20 Plus Year Treasury Bond ETF (TLT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 20 Plus Year Treasury Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 23.6× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 20 Plus Year Treasury Bond ETF for 83 Days and GeneDx Holdings Corp for 19 Days on average.
| TLT | WGS | |
|---|---|---|
Market Cap | $47.61B | $2.02B |
Volume | 49,263,490 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $92.06 | $167.51 |
52-Week Low | $77.11 | $34.51 |
Typical Hold Time | 83 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.87, up 0.94% on the day but remains in a prolonged downtrend, down 11% year-to-date and 46% over five years. The technical picture is bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights a challenging bond market environment with Treasury yields reaching multi-decade highs, creating headwinds for long-duration bond funds.
The outlook for TLT remains heavily dependent on interest rate direction, with current high yields offering potential income but significant price risk if rates continue rising. Key investment considerations include duration risk exposure, inflation expectations, and Federal Reserve policy shifts. The fund's dividend payments provide income, but capital preservation remains challenging in the current rising rate environment.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
